Michael D Howe
Overview
Explore the profile of Michael D Howe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
45
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Varshney A, Jia Z, Howe M, Keiler K, Baughn A
bioRxiv
. 2024 Nov;
PMID: 39554143
poses a serious challenge for human health, and new antibiotics with novel targets are needed. Here we demonstrate that an acylaminooxadiazole, MBX-4132, specifically inhibits the -translation ribosome rescue pathway to...
2.
Ostrer L, Crooks T, Howe M, Vo S, Jia Z, Hegde P, et al.
bioRxiv
. 2024 Oct;
PMID: 39416067
Pyrazinamide (PZA) is a cornerstone of first-line antitubercular drug therapy and is unique in its ability to kill nongrowing populations of through disruption of coenzyme A synthesis. Unlike other drugs,...
3.
Cole M, Howe M, Buonomo J, Sharma S, Lamont E, Brody S, et al.
Chemistry
. 2022 Jun;
28(51):e202200995.
PMID: 35697660
Tuberculosis (TB) is a leading source of infectious disease mortality globally. Antibiotic-resistant strains comprise an estimated 10 % of new TB cases and present an urgent need for novel therapeutics....
4.
Hegde P, Howe M, Zimmerman M, Boshoff H, Sharma S, Remache B, et al.
Eur J Med Chem
. 2022 Feb;
232:114201.
PMID: 35219151
Tuberculosis (TB) is one of the world's most deadly infectious diseases resulting in nearly 1.3 million deaths annually and infecting nearly one-quarter of the population. para-Aminosalicylic acid (PAS), an important...
5.
Thiede J, Dillon N, Howe M, Aflakpui R, Modlin S, Hoffner S, et al.
mBio
. 2022 Feb;
13(1):e0043921.
PMID: 35100871
Pyrazinamide (PZA) plays a crucial role in first-line tuberculosis drug therapy. Unlike other antimicrobial agents, PZA is active against Mycobacterium tuberculosis only at low pH. The basis for this conditional...
6.
Simonson A, Mongia A, Aronson M, Alumasa J, Chan D, Lawanprasert A, et al.
Nat Biomed Eng
. 2021 Jan;
5(5):467-480.
PMID: 33390588
Precision antimicrobials aim to kill pathogens without damaging commensal bacteria in the host, and thereby cure disease without antibiotic-associated dysbiosis. Here we report the de novo design of a synthetic...
7.
Bockman M, Engelhart C, Cramer J, Howe M, Mishra N, Zimmerman M, et al.
ACS Infect Dis
. 2019 Jan;
5(4):598-617.
PMID: 30652474
The synthesis, absolute stereochemical configuration, complete biological characterization, mechanism of action and resistance, and pharmacokinetic properties of ( S)-(-)-acidomycin are described. Acidomycin possesses promising antitubercular activity against a series of...
8.
Howe M, Kordus S, Cole M, Bauman A, Aldrich C, Baughn A, et al.
Front Cell Infect Microbiol
. 2018 Nov;
8:399.
PMID: 30483484
-Aminosalicylic acid (PAS) is a second-line anti-tubercular drug that is used for the treatment of drug-resistant tuberculosis (TB). PAS efficacy in the treatment of TB is limited by its lower...